This review focuses on the role of incretin-based therapies, particularly Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, in managing diabetes and its complications
Despite showing clear clinical signs of B12 deficiency, doctors often misdiagnose or ignore these people because their results fall within a good B12 level range
studies have demonstrated the efficacy of GLP-1 RAs in slowing the progression of diabetic kidney disease [22]
temporary digestive changes can occur when beginning 2
Many patients choose a four-week cycle: week one on the right abdomen, week two on the left abdomen, week three on the right thigh, and week four on the right arm
The question is not whether side effects occur but which ones, how severe, and how long they last